anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1510569 Devices for administering medicaments percutaneously AMERICAN HOME PRODUCTS CORP 2 July 1976 27752/76 Heading A5R A device for percutaneous administration of a medicament to a moist body surface comprises a moisture - impervious support member 12 formed from an inert flexible film, a recess 14 preformed in the film, a moistureactivatable adhesive 16 covering the film surface about the recess and a medicament 20 in the recess. More than one recess may be provided in the support member for administering different medicaments. A layer of moisture - impervious material, Figs. 5 and 6 (not shown), may be provided between the member 12 and adhesive 16. The adhesive may extend over the surface of the recess (as shown) and thus be used to hold the medicament or the surface of the recess may be free of adhesive Fig. 6 (not shown). The exposed medicament and the adhesive - coated surface may be covered with a protective layer 24 for transport and storage. The support member may be ethylcellulose, ethylmethylcellulose, or cellulose acetate phthalate and may include castor oil as a plasticiser, The adhesive may comprise a hydrocolloid mixed with a binder such as polyvinylpyrrolidone or may be karay gum in a viscous solution of polyvinylpyrrolidone and polyethylene glycol. The moisture - impervious layer may be an isobutylene - isoprene copolymer. The medicament may be pure or may be mixed with semi - solids or solids melting at body temperature, and may include adjuvants for controlling the pH and the rate of absorption of the medicament through the skin. The device may be used as a buccal tape and may be square, rectangular or circular.
The invention discloses a bisulfonyl anthracenedione dioxime derivative serving as P2X<3> and P2X<2/3> receptor antagonists. The invention relates to a compound shown as a formula I and/or pharmaceutical salts thereof, a preparation method of the compound and/or pharmaceutical salts thereof, as well as a pharmaceutical composition containing the compound. The compound and the pharmaceutical salts thereof can be treating and/or preventing P2X<3> and P2X<2/3> receptor mediated diseases such as frequent micturition, urgent urination, uracratia, spontaneous bladder hypersensitivity, prostatitis, urocystitis, pain illnesses, and the like. The structural formula is as shown in the specification. If the substitution position of sulfonyl connected with R1 on an anthracene ring is defined as a position 2 of anthracene, a substitution position of sulfonyl connected with R2 on an anthracene ring is defined as a position 6 or 7, and 2,6- or 2,7-bis-substituted sulfonyl anthracene 9,10-diketone dioxime derivatives are formed. The R1 and R2 are independently selected from C1-C6 straight chain or branched alkyl, 3-8-membered alicyclic groups, aryl and heterocyclic aryl.
The primary objective of this phase IV, randomized, placebo controlled clinical trial is to determine the incremental effect of amoxicillin treatment compared with symptomatic treatments on disease-related quality of life in adults with clinically diagnosed acute bacterial rhinosinusitis. The secondary objective is to determine the incremental effect of amoxicillin treatment compared with symptomatic treatments on functional status, symptoms, disease recurrence, satisfaction with treatment, and direct costs of treatment in adults with clinically diagnosed acute bacterial rhinosinusitis. The tertiary objective is to identify prognostic indicators for clinical improvement with antibiotic treatment in adults with clinically diagnosed acute bacterial rhinosinusitis. Two hundred adult subjects, 18 to 70 years old, who meet the recommended criteria for acute bacterial rhinosinusitis, will be enrolled from 8 practice sites. Subjects will be randomized to receive a 10-day course of either amoxicillin or placebo. In addition, all subjects will receive an analgesic, an oral decongestant, a nasal saline spray, and an antitussive agent. Subject outcomes will be assessed by telephone interview at 0, 3, 7, 10, and 28 days. The primary outcome is the disease-specific quality of life at Day 3 measured with the SNOT-16, a validated evaluative instrument. Secondary outcomes include change in functional status and symptoms, disease recurrence, satisfaction with care and the direct costs of treatment. Tertiary outcome measures include possible subject and disease-related factors that predict clinical improvement with antibiotic treatment at Day 3 for use in future studies to aid clinical decision-making.
Patients of the group received supplemental nutritional support with Nutridrink ONS 200 ml, 2 bottles (400 ml) daily for 28 days from the date of inclusion. In a hospital setting, additional nutritional support will be added to the patient's standard hospital diet. After being discharged from the hospital, the patient will receive at his disposal the required amount of Nutridrink ONS 200 ml in amount of 400 ml per day and will take it in addition to his usual and habitual diet. The Nutridrink ONS 200 ml is recommended to be taken between main meals.
BACKGROUND: Macrophage-derived extracellular vesicle (macrophage-EV) is highly studied for its regulatory role in atherosclerosis (AS). Our current study tried to elucidate the possible role of macrophage-EV loaded with small interfering RNA against high-mobility group box 1 (siHMGB1) affecting atherosclerotic plaque formation.
METHODS: In silico analysis was performed to find critical factors in mouse atherosclerotic plaque formation. EVs secreted by RAW 264.7 cells were collected by ultracentrifugation and characterized, followed by the preparation of macrophage-EV-loaded siHMGB1 (macrophage-EV/siHMGB1). ApoE-/- mice were used to construct an AS mouse model by a high-fat diet, followed by injection of macrophage-EV/siHMGB1 to assess the in vivo effect of macrophage-EV/siHMGB1 on AS mice. RAW264.7 cells were subjected to ox-LDL, LPS or macrophage-EV/siHMGB1 for analyzing the in vitro effect of macrophage-EV/siHMGB1 on macrophage pyrophosis and inflammation.
RESULTS: In silico analysis found that HMGB1 was closely related to the development of AS. Macrophage-EV/siHMGB could inhibit the release of HMGB1 from macrophages to outside cells, and the reduced HMGB1 release could inhibit foam cell formation. Besides, macrophage-EV/siHMGB also inhibited the LPS-induced Caspase-11 activation, thus inhibiting macrophage pyroptosis and preventing atherosclerotic plaque formation.
CONCLUSION: Our results proved that macrophage-EV/siHMGB could inhibit foam cell formation and suppress macrophage pyroptosis, finally preventing atherosclerotic plaque formation in AS mice.
The present invention relates to Sanqi instant powder. The present invention is characterized in that food is prepared from the following main raw materials by the weight ratio: 1.0 to 4.0 of radix notoginseng and 0.2 to 1.5 of chrysanthemum; according to the ratio, 1.0 to 3.0 of kudzuvine root, 3 to 5 of lactose and 0.01 to 0.1 of aspartame are added, the Sanqi instant powder is prepared through extraction by a certain scientific method. The health food of the present invention is scientifically prepared, and the mouth feeling is palateful and sweet. The Sanqi instant powder contains no sugar, can be eaten by diabetes persons, and has favorable function of health protection. By effect measurement, the Sanqi instant powder has the functions of repairing and regenerating hepatic cells, postpones hepatic fibrosis process, and has the prevention function to hepatic injury. By passing the effect experiment relevant to health food by national health ministry, the Sanqi instant powder is proved to have the effects of protecting the liver and improving the oxygen deficiency resistant capability. After the Sanqi instant powder is administered, persons feel comfortable and refreshing, and are full of vigor.
The present invention relates to the application of ginseng rhizomes and a method thereof by utilizing soild element granules prepared from ginseng. The present invention points out that ginseng rhizomes have the same efficiency and the same function of a main root of ginseng. The method of the present invention alters a traditional manufacturing method for removing ginseng rhizomes. The ginseng rhizomes are manufactured into ginseng rhizome extraction powder after cleaning, extraction, concentration, drying and pulverization. The soild element granules are manufactured through mixing and granulating the ginseng rhizome extraction powder and coarse polysaccharide powder of membranous milkvetch root, and can obviously improve the macrophage function and the formation rate of E-rosettes. Besides, the soild element granules can make the overmuch Ts cells of a tumour patient in a late period bear definite inhibition, and have definite protection and improvement function for the white cells of a patient who is in radiotherapy and chemotherapy.
Compositions and methods are provided which can be utilized in active immunization as a prophylactic treatment or a therapeutic treatment for tumors. The compositions are employed as injectable tumor vaccines or as preparations for intratumoral administration and are capable of stimulating immune responses to specific tumor antigens. The tumor vaccines are composed of an antigenic cellular material including a plurality of inactivated tumor cells or tumor cell portions, a depot material, and an immunostimulant adsorbed to the depot material. The depot material with absorbed immunostimulant is mixed with the tumor cells or tumor cell portions to form the vaccine compositions. The preparations for intratumoral administration include the depot material adsorbed immunostimulant without the antigenic cellular material. The immunostimulant adsorbed to the depot material permits release of biologically active quantities of the immunostimulant over a period of time rather than all at once.
PURPOSE:To obtain a pharmaceutical composition containing yeast extract effective for improving the drug action of a Chinese galenical drug and stabilizing the physical and chemical properties of the composition by using a Chinese galenical drug in combination with a yeast extract. CONSTITUTION:The objective pharmaceutical composition containing yeast extract can be prepared by adding yeast extract (especially) bear yeast extract) to a Chinese galenical drug [especially REISHI (fruit body of Ganoderma lucidum)]. In the case of using REISHI as the Chinese galenical drug, the amount of the yeast extract is 0.1-10 pts.wt. per 1 pts.wt. of REISHI. The useful component of yeast extract having high nutritive value improves the drug action of the Chinese galenical drug such as REISHI to achieve an excellent pharmacological action compared with the single use of the Chinese galenical drug. Accordingly, the composition can be extracted to be useful as a Chinese galenical drug preparation. When REISHI is used especially as the Chinese galenical drug, the composition has excellent effect to improve the learning and memory functions and is useful as an antidemential agent.
The global aim of this study is to evaluate an "integrated" treatment approach for cocaine dependent patients with comorbid unipolar depression. It is hypothesized that a cognitive-behavioral psychotherapy that targets both disorders, in combination with a pharmacotherapy, i.e., bupropion, is expected to provide the best coverage for dual disorders and thus maximize treatment outcomes. Specifically, we will conduct a double blind, placebo-controlled clinical trial involving the random assignment of participants into one of four treatment conditions according to a full 2x2 factorial research design. One independent variable will be pharmacotherapy (bupropion versus placebo); the other independent variable will be psychotherapy (integrated CBT versus clinical management). The study will enroll 140 cocaine dependent patients with comorbid major depressive disorder. A secondary objective is to further elucidate "primary" and "secondary" paradigms of depressive illness symptoms in cocaine-dependent adults and better understand how this distinction influences treatment outcome. This will be accomplished by enrolling a subsample of patients with substance-induced mood disorder. Taken together, this proposal will examine the feasibility and relative efficacy of a novel integrated treatment model for dually-diagnosed patients.
The invention discloses a health product for improving sleep and a preparation method and the application thereof. The health product for improving the sleep, provided by the invention, is mainly prepared by the following raw materials in parts by weight: 65 parts to 260 parts of glossy ganoderma, 50 parts to 167 parts of epimedium, and 125 parts to 375 parts of jujube seeds. Animal experiments prove that the health product provided by the invention has the function of improving the sleep of the animals. In the experiments on the influence of extending nembutal sleeping hour, compared with a medium dosage group and a control group, the sleeping hour of the animals is extended, and differences have statistical significance (P<0.05). In the experiments on the influence of the sleep occurring rate at nembutal subthreshold dosage, compared with the medium dosage group and the control group, the differences of the sleep occurring rate of the animals have statistical significance (P< 0.05). In the experiments on the influence of barbital sodium sleep latency, compared with a high dosage group and the control group, the falling-asleep latency time of the animals is shortened, and the differences have the statistical significance (P< 0.05).
This invention teaches a novel treatment of patients infected with influenza virus in early stages of the disease, with liposomes called α-gal/SA liposomes, in order to decrease the infection period and decrease further complications by this disease. The treatment is based on inhalation of biodegradable liposomes that present two types of carbohydrate epitopes: α-Gal epitopes with the structure Galα1-3Galβ1-4(3)GlcNAc-R) and sialic acid (SA) epitopes. The treatment is based on the ability of influenza virus to bind to SA epitopes and on the binding of the natural anti-Gal antibody (the most abundant natural antibody in humans) to α-gal epitopes. Following inhalation of aerosolized α-gal/SA liposomes they land in the mucus lining the respiratory tract. The α-gal/SA liposomes bind influenza virus via SA epitopes interaction with hemagglutinin of the virus, thus they slow or prevent the progress of the influenza virus infection process. Binding of the natural anti-Gal antibody to α-gal epitopes on α-gal/SA liposomes causes complement mediated chemotactic recruitment of macrophages and dendritic cells which internalize via Fc/Fc receptor interaction the α-gal/SA liposomes and the influenza virus bound to them and destroy this virus. The recruited macrophages and dendritic cells further process the immunogenic peptides of the internalized virus, transported them to the regional lymph nodes and present these peptides for eliciting an effective protective immune response that ends the influenza virus infection in a period shorter than in untreated patients and prevents further complications in the respiratory system and in other parts of the body.
Acute on chronic liver failure (ACLF) is a clinically critical illness and has been extensively researched around the world. However, there is a potential "communication barrier" in the ACLF study; that is, different countries and regions, or different research collaboration groups, follow different ACLF definitions and related standards, making researchers in this field confuse in understanding the research value of relevant research and interpreting the research results. Important differences exist in the Asia-Pacific region and North America and Europe, such as the etiology, the clinical characteristics of the patient group, the requirements for cirrhosis, and the predisposing factors of the disease, making it necessary for China or the Asia-Pacific region to develop appropriate ACLF diagnosis standards and prognosis. In recent years, Chinese experts have also focused on the research progress of APASL ACLF Research Consortium (AARC) in the Asia-Pacific region. It is found that the AARC standards are more suitable for the diagnosis and treatment of patients with ACLF in China than the Western standards. The ACLF prediction model (TPPM model) established by Professor Qin.N's team predicts that the prognostic efficacy of patients with HBV-ACLF is significantly better than that of Western prognosis. The AARC China Study is to establish a widely recognized and harmonized standard of patients with HBV-ACLF in the Asia Pacific region.
Follow these instructions unless otherwise instructed by your dental professional:

  1. Adults and children 12 years of age and older: Apply at least 1 inch strip of PreviDent® 5000 Sensitive onto a soft bristle toothbrush. Brush teeth thoroughly for at least 1 minute, expectorate, and rinse mouth thoroughly.
  2. Use twice a day (morning and evening) or as recommended by a dentist or physician. Make sure to brush all sensitive areas of the teeth. Children under 12 years of age: Consult a dentist or physician.
In this study, carrilizumab combined with sovantinib in the second-line treatment of patients with advanced or metastatic cholangiocarcinoma with single arm, open, Exploratory clinical trials.The specific treatment regimen was carrilizumab 200mg Q3W d1; Sofantinib: 300mg,Take orally, once a day, continuously. Treatment continues or until disease progression occurs or the patient becomes intolerant to treatment regimens.The efficacy was evaluated every 2 cycles.
The short agonist protocol was started on cycle day 1 with triptorelin (Decapeptyl Ferring Pharmaceuticals, Germany) 0.05 mg/day S.C. Human menopausal gonadotropin IM daily (HMG 75 IU, Merional, IBSA) were also administered starting from days 2 to 3 of cycle. The dose was adjusted for each patient according to the diameter of the follicles detected in their follow up ultrasound. Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
The present invention discloses a Chinese wolfberry and mulberry health-care combination. The combination is prepared by the following raw materials in parts by weight: salvia miltiorrhiza, pseudo-ginseng, fructus ligustri lucidi, mulberry, etc. The combination is meticulously studied, and is reasonable in collocation, scientific in formula, targeted in drug use for the human heart, brain, kidney, lung, liver, and other organs. The above-mentioned traditional Chinese medicines belong to the food and medicine homologous food, and are safe and non-toxic. The combination has no toxic side effects with long-term use, and is mild in drug properties. The combination can also enhance immunity, adjust blood pressure, blood glucose and blood fat of human bodies, and not only has health care and prevention effects, but also has certain therapeutic effects for many common diseases in various human organs.
FIELD: chemistry. ^ SUBSTANCE: present invention relates to four defined crystalline polymorphous forms of the monohydrate of a compound A having the following chemical composition: ^ . ^ Compound A. These four polymorphous forms, denoted here as forms I, II, III and IV, exhibit CXC chemokine receptor ligand activity. ^ EFFECT: invention relates to a pharmaceutical composition based on said compounds, to use thereof for treating different diseases and to methods for synthesising the said polymorphous forms. ^ 58 cl, 2 tbl, 4 dwg
Prostatic cancer is one of the most common malignancies in males and is the second leading cause of cancer-related deaths in males worldwide. The burden is expected to grow 1.7 million new cases and 499,000 new deaths by 2030. Although the diagnosis of prostatic carcinoma can usually be made on histological features, nowadays many immunohistochemical (IHC) markers are used to distinguish it from benign mimickers as well as in predicting prognosis and treatment. Out of these markers, Ets-related gene (ERG product) is a proto-oncogene which participates in chromosomal translocations and is frequently over expressed in prostatic carcinoma which harbors ERG-transmembrane protease, serine 2 fusion. ERG is a transcription factor belonging to the erythroblast transformation-specific (ETS) family. It is involved in many important cellular processes including differentiation, cell proliferation, angiogenesis, cell migration, hematopoiesis, and apoptosis. This proto-oncogene is expressed in the urogenital tract and hematopoietic cells. Gene fusions involving sequences of transmembrane protease serine 2 (promoter of TMPRSS2) and protein coding sequences of ERG result in over expression of ERG in prostatic tumors. This TMPRSS2-ERG fusion has been shown to occur in 50-70% cases of prostatic acinar adenocarcinoma in different studies. Genetic rearrangements were not identified in epithelial carcinomas until Tomlins et al. demonstrated ERG gene fusions in prostatic carcinoma.The presence of this fusion is now believed to be a critical event in the development of prostatic carcinoma.

TMPRSS2-ERG fusion results in constitutive expression of ERG oncoprotein resulting in enhanced proliferation and invasive potential of prostatic cancer cells. Moreover, TMPRSS2-ERG fusion gene product can be an important therapeutic target in prostatic cancer. Immunohistochemical (IHC) expression of ERG oncoprotein may serve as a surrogate biomarker of TMPRSS2-ERG fusion gene. Therefore in the present study we aimed to evaluate the ERG expression in prostatic acinar adenocarcinoma and its association with clinicopathological features.
The control group will consist of 600 children from the original cohort (300) and comparable cohort (300). The control group will meet twice a month for four months at community centers. During these sessions, investigators will teach a curriculum that is not related to knowledge, attitudes, and habits towards healthy lifestyles.
BACKGROUND: Gastric epithelial barrier disruption constitutes a crucial step in gastric cancer (GC). We investigated these disruptions during the Correa's cascade timeline to correlate epithelial barrier dysfunction.
MATERIALS AND METHODS: This study was conducted as a single-center, non-randomized clinical trial in China from May 2019 to October 2022. Patients with chronic atrophic gastritis (CAG), gastric intestinal metaplasia (GIM), low-grade intraepithelial neoplasia (LGIN), high-grade intraepithelial neoplasia (HGIN), and intramucosal carcinoma underwent probe-based confocal laser endomicroscopy (pCLE). The pCLE scoring system was used to assess gastric epithelial barrier disruption semi-quantitatively.
RESULTS: We enrolled 95 patients who underwent a pCLE examination. The control group consisted of 15 individuals, and the experimental group included 17 patients with CAG, 27 patients with GIM, 20 patients with LGIN, and 16 patients with early gastric cancer (EGC). Apart from CAG, which showed no significant difference compared to the control group, a significantly higher incidence of gastric epithelial barrier damage was found in the GIM, LGIN, and EGC groups compared to the control group (Kruskal-Wallis H test = 69.295, p < 0.001). There is no difference in LGIN patients between GIM and LGIN areas, and there is no difference between the two groups compared with the EGC group. The intestinal metaplasia area in LGIN patients causes more severe gastric epithelial damage compared to that in non-LGIN patients. Additionally, compared to control group, a significant difference (p < 0.001) was noted between individuals with Helicobacter pylori-positive atrophic gastritis and those with IM, whereas no significant difference (p > 0.05) was observed among individuals with H. pylori-negative atrophic gastritis.
CONCLUSIONS: The gastric epithelial barrier remains dysfunctional from the initiation of H. pylori infection to GC progression. Beyond the "point of no return," subsequent carcinogenesis processes may be attributed to other mechanisms.